APA

de Vries-van der Weij J., de Haan W., Hu L., Kuif M., Oei H. L. D. W., van der Hoorn J. W. A., Havekes L. M., Princen H. M. G., Romijn J. A., Smit J. W. A. & Rensen P. C. N. (20090608). Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. : Endocrinology.

Chicago

de Vries-van der Weij Jitske, de Haan Willeke, Hu Lihui, Kuif Maarten, Oei H Ling D W, van der Hoorn José W A, Havekes Louis M, Princen Hans M G, Romijn Johannes A, Smit Johannes W A and Rensen Patrick C N. 20090608. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. : Endocrinology.

Harvard

de Vries-van der Weij J., de Haan W., Hu L., Kuif M., Oei H. L. D. W., van der Hoorn J. W. A., Havekes L. M., Princen H. M. G., Romijn J. A., Smit J. W. A. and Rensen P. C. N. (20090608). Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. : Endocrinology.

MLA

de Vries-van der Weij Jitske, de Haan Willeke, Hu Lihui, Kuif Maarten, Oei H Ling D W, van der Hoorn José W A, Havekes Louis M, Princen Hans M G, Romijn Johannes A, Smit Johannes W A and Rensen Patrick C N. Bexarotene induces dyslipidemia by increased very low-density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-density lipoprotein. : Endocrinology. 20090608.